AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RAPP

Ignelzi Troy A. purchased $144K of RAPP

Ignelzi Troy A. (Chief Financial Officer) purchased 5,500 shares of Rapport Therapeutics, Inc. (RAPP) at $26.10 ($0.14M total) on 2026-10-21.

Original reporting
SEC EDGAR · Ignelzi Troy A.
Published Oct 21, 2026, 9:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RAPP
Neutral
medium confidence
Mentioned
$RAPP
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RAPPNeutralLow
01

Why it matters

The CFO's purchase adds a modest bullish bias but is unlikely to move the stock significantly.

02

Market read

A small insider buy provides a mild positive cue but lacks material impact.

03

What to watch

Potential upcoming clinical milestones could make the insider's timing more meaningful.

Relevance 5/10Novelty 3/10Timing: same-day filing

Background

Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$RAPPNeutralMedium confidence
Context

CFO Ignelzi Troy A. bought 5,500 shares of Rapport Therapeutics for $143,550, increasing his stake to 15,500 shares.

Expected impact

modest upward pressure as the market prices in the CFO's buy

Evidence & confidence

A $144K purchase by the CFO is a positive signal but the amount is small relative to the company's market cap, limiting any material price move.

Market effects

Sector

No broader sector impact; the filing is company‑specific.

Regional

Limited to U.S. investors tracking Rapport Therapeutics.

Global

None

Counterpoint

What could challenge this read

The purchase may be routine portfolio rebalancing rather than a strong conviction signal.

Key entities

  • Company
    Rapport Therapeutics, Inc.

    Biopharmaceutical company developing therapies for rare diseases.

  • Individual
    Ignelzi Troy A.

    Chief Financial Officer of Rapport Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RAPP insider trading history →

Related articles

$RAPPMed

Rapport Therapeutics 3Q 2026: Revenue $0 Net loss $40.2M, EPS $(0.84) — 10-Q Summary

Rapport Therapeutics reported no revenue and a net loss of $40.2M in 3Q 2026, widening from a $26.9M loss in the prior-year quarter. Diluted EPS was $(0.84). The company began Phase 3 trials for RAP-219 in epilepsy and plans further trials in 2027. Collaboration revenue from Tenacia was $20M for the nine months. According to the company, they deferred one program and prioritized another.

tradingview.com
$RAPPHighAI 9/10

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label

SEC EDGAR 8-K
$RAPPMedAI 9/10

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Therapeutics (RAPP) closed public offerings of 9.76M shares of common stock at $21.00 per share, $172.5M in convertible notes, and a concurrent private placement of 1.43M shares. Total net proceeds are approximately $410.7M. Proceeds will fund clinical trials, R&D, and general corporate purposes. The notes have a 2.25% interest rate and mature in 2032.

finance.yahoo.com